Rating Change #3
Qiagen (QGEN) has been downgraded by TheStreet Ratings from buy to hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity.
Highlights from the ratings report include:
- Reflecting the weaknesses we have cited, including the decline in the company's earnings per share, QGEN has underperformed the S&P 500 Index, declining 6.91% from its price level of one year ago. Looking ahead, other than the push or pull of the broad market, we do not see anything in the company's numbers that may help reverse the decline experienced over the past 12 months. Despite the past decline, the stock is still selling for more than most others in its industry.
- The company's current return on equity has slightly decreased from the same quarter one year prior. This implies a minor weakness in the organization. In comparison to the other companies in the Life Sciences Tools & Services industry and the overall market, QIAGEN NV's return on equity is significantly below that of the industry average and is below that of the S&P 500.
- The gross profit margin for QIAGEN NV is rather high; currently it is at 64.60%. Despite the high profit margin, it has decreased significantly from the same period last year. Despite the mixed results of the gross profit margin, the net profit margin of 11.80% trails the industry average.
- The current debt-to-equity ratio, 0.34, is low and is below the industry average, implying that there has been successful management of debt levels. Along with this, the company maintains a quick ratio of 3.18, which clearly demonstrates the ability to cover short-term cash needs.
- Despite its growing revenue, the company underperformed as compared with the industry average of 13.5%. Since the same quarter one year prior, revenues slightly increased by 7.4%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
QIAGEN N.V., through its subsidiaries, provides sample and assay technologies. The company has a P/E ratio of 28.1, below the average drugs industry P/E ratio of 29.5 and above the S&P 500 P/E ratio of 17.7. Qiagen has a market cap of $4 billion and is part of the health care sector and drugs industry. Shares are down 13% year to date as of the close of trading on Friday.You can view the full Qiagen Ratings Report or get investment ideas from our investment research center.